CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 101 enrolled
Drug / intervention
Quadrivalent Live Attenuated Influenza Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02474901
NCT02474901Phase 2Completed
CompareCT.gov

Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults

University of Colorado, Denver·interventional·Posted Jun 18, 2015·Updated Nov 20, 2017

In Brief

A Phase 2 clinical trial evaluating Quadrivalent Live Attenuated Influenza Vaccine for Human Immunodeficiency Virus (HIV). Completed, enrolled 101 participants across 1 site.

Detailed Summary

The goal of this study is to determine if there is a difference in shedding (primary objective) and in immunogenicity and safety (secondary objectives) between HIV-positive and HIV-negative children and young adults who are receiving the quadrivalent live-attenuated influenza vaccine (QLAIV).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus (HIV)
CountriesUnited States
CollaboratorsMedImmune LLC

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 18, 2015
Enrollment StartJul 1, 2013
Primary CompletionMar 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.0 years ago

Interventions

Quadrivalent Live Attenuated Influenza Vaccinebiological